Personalized Partnering: Drug, Dx Firms Should Team, Not Necessarily Merge
This article was originally published in The Gray Sheet
Executive Summary
Industry leaders disagree on whether collaborations or mergers are the best structure for effective drug/diagnostic collaborations
You may also be interested in...
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
FDA Diagnostics Office Seeks Bigger Role In Personalized Medicine
FDA officials that regulate lab tests don't think they have been active enough in the policy debate over the future of personalized medicine; but, they say, that is about to change